AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-15864633_ITM" title="Facts and information about Metronidazole gel approved.(PRODUCTS)">Metronidazole gel approved.(PRODUCTS)</a>
Close
Set up an RSS feed that alerts you when new articles from OB GYN News are available.
Frequently asked questions about RSS feeds
Metronidazole gel approved.(PRODUCTS)
Metronidazole vaginal gel (0.75%) is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Metronidazole gel approved.(PRODUCTS)(Brief Article)
- Magazine article from: Internal Medicine News August 1, 2005 700+ words
Metronidazole vaginal gel (0.75%) is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis) in nonpregnant women. For more information, contact Teva
- Metronidazole gel bests placebo for recurrent BV: ongoing study.(Gynecology)
- Magazine article from: OB GYN News McNamara, Damian February 15, 2004 700+ words
...vaginosis treated with vaginal metronidazole gel had a lower recurrence...the suppressive action of metronidazole gel. A total of 157 women...The women applied 5 g metronidazole gel at bedtime during a 10...
- For recurrent BV, stay with metronidazole gel.(Women's Health)(bacterial...
- Magazine article from: Family Practice News Bates, Betsy February 15, 2008 700+ words
SAN DIEGO -- Long-term use of metronidazole gel remains the mainstay of treatment...Patients are advised to use intravaginal metronidazole gel 0.75% at bedtime for 10-14 days...there are no good alternatives to metronidazole gel for these patients, she noted...
- Assessment of skin barrier function in rosacea patients with a novel 1%...
- Magazine article from: Journal of Drugs in Dermatology Draelos, Zoe D. September 1, 2005 700+ words
...irritation and barrier disruption. A 2-week study was undertaken by the author to evaluate the effect of the new 1% metronidazole gel on the skin barrier in 25 women with mild to moderate rosacea. Statistically significant improvement in disease severity...
- Cumulative irritation potential of metronidazole gel compared to azelaic acid...
- Magazine article from: Journal of Drugs in Dermatology Ziel, Kristin Yelverton, Christopher B. Balkrishnan, Rajesh Feldman, Steven R. November 1, 2005 700+ words
Abstract Background: Metronidazole 0.75% gel and azelaic acid 15% gel are commonly used to treat rosacea. Irritation is a common side effect. Objective: To assess the cumulative irritation potential of metronidazole 0.75% gel and azelaic acid 15% gel. Methods: Metronidazole 0.75% gel, azelaic acid
- Efficacy of topical azelaic acid 15% gel plus Anti-Inflammatory dose...
- Magazine article from: Journal of Drugs in Dermatology June 1, 2009 700+ words
Sponsored by Intendis GmbH. In this study, subjects with moderate papulopustular rosacea will be treated either with azelaic acid 15% gel topically plus an anti-inflammatory dose of doxy-cyline (40mg)daily or with metronidazole 1% gel topically once daily plus an anti-inflammatory dose of
- Positive Results of Phase 4 Clinical Study Evaluating Effects of Oracea(TM)...
- Press release article from: Business Wire February 2, 2007 700+ words
Patients in the Oracea + MetroGel Group Experienced a Mean Reduction of 13.9 Inflammatory Lesions Compared to 8.5 in the Placebo + MetroGel Group NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced results of a Phase 4 clinical study designed to evaluate the efficacy of
- Gel approved.(RXs)(Barrier Therapeutics Inc.)(Brief article)
- Magazine article from: Chain Drug Review August 28, 2006 700+ words
Barrier Therapeutics Inc. has received approval of Xolegel for the treatment of seborrheic dermatitis. The condition affects about 3% to 5% of the population. Xolegel was the second product clearance of the year for the Princeton, N.J.-based pharmaceutical firm.
